Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc monthly Stock Chart
AGN [NYSE]
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-12.52 Insider Own0.10% Shs Outstand339.10M Perf Week2.06%
Market Cap64.77B Forward P/E11.42 EPS next Y16.73 Insider Trans-3.82% Shs Float338.35M Perf Month2.65%
Income-4187.20M PEG- EPS next Q4.01 Inst Own87.20% Short Float0.89% Perf Quarter10.16%
Sales16.16B P/S4.01 EPS this Y-543.10% Inst Trans0.06% Short Ratio1.65 Perf Half Y20.44%
Book/sh210.10 P/B0.91 EPS next Y2.45% ROA-1.60% Target Price214.16 Perf Year-3.43%
Cash/sh5.00 P/C38.18 EPS next 5Y6.47% ROE-2.60% 52W Range142.81 - 197.33 Perf YTD16.76%
Dividend2.88 P/FCF12.32 EPS past 5Y9.51% ROI-2.10% 52W High-3.87% Beta1.12
Dividend %1.51% Quick Ratio0.80 Sales past 5Y21.90% Gross Margin86.60% 52W Low32.82% ATR4.18
Employees17800 Current Ratio1.00 Sales Q/Q2.90% Oper. Margin-19.10% RSI (14)51.27 Volatility2.47% 2.23%
OptionableYes Debt/Eq0.36 EPS Q/Q40.70% Profit Margin-11.00% Rel Volume0.73 Prev Close191.00
ShortableYes LT Debt/Eq0.34 EarningsOct 30 BMO Payout- Avg Volume1.84M Price189.68
Recom2.10 SMA200.14% SMA500.66% SMA20010.39% Volume699,890 Change-0.69%
Oct-09-18Resumed Guggenheim Buy
Apr-24-18Resumed Citigroup Buy $200
Apr-23-18Resumed Evercore ISI Outperform
Apr-17-18Initiated Stifel Hold $192
Feb-23-18Initiated SunTrust Buy $200
Feb-07-18Reiterated Leerink Partners Outperform $237 → $242
Dec-07-17Downgrade Argus Buy → Hold
Nov-29-17Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-27-17Resumed Leerink Partners Outperform $237
Nov-02-17Reiterated RBC Capital Mkts Outperform $250 → $221
Oct-19-17Reiterated RBC Capital Mkts Outperform $277 → $250
Oct-17-17Reiterated UBS Buy $275 → $255
Oct-02-17Reiterated Barclays Equal Weight
Sep-25-17Reiterated RBC Capital Mkts Outperform $285 → $277
Sep-20-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-16-17Initiated Cantor Fitzgerald Neutral $231
Jun-09-17Reiterated Mizuho Buy $275 → $267
May-10-17Reiterated RBC Capital Mkts Outperform $279 → $284
May-10-17Downgrade Goldman Buy → Neutral
Feb-09-17Reiterated Mizuho Buy $273 → $275
Oct-17-18 09:40AM  Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes? Zacks
07:44AM  Allergan plans to file for U.S. approval of new migraine drug by Q1 of 2019 MarketWatch
07:30AM  Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine PR Newswire
06:00AM  5 Blue Chip Drug Stocks Poised for Long-Term Gains Investopedia
Oct-16-18 09:00AM  FDA Approves Medicines360's sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years PR Newswire
Oct-11-18 04:15PM  Allergan To Present Data From 13 Abstracts At The 2018 American Society For Dermatologic Surgery Meeting In Phoenix PR Newswire
Oct-09-18 04:35PM  Better Buy: Crispr Therapeutics AG vs. Editas Motley Fool
Oct-08-18 08:00AM  Allergan Presents New Research at the American College of Gastroenterology Annual Scientific Meeting (ACG 2018) PR Newswire
Oct-05-18 07:30AM  Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease PR Newswire
Oct-04-18 07:30AM  Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting® PR Newswire
Oct-03-18 10:37AM  Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara Zacks
08:29AM  Health care just posted its best quarter in 5 years, but there's still value to be found says trader CNBC
07:45AM  Allergan Launches New JUVÉDERM® IT Campaign Designed To Reach The Next Generation Of Consumers PR Newswire
Oct-01-18 05:30PM  Genentech's first scientist now focused on Bay Area's latest biotech IPO American City Business Journals
08:00AM  Allergan to Report Third Quarter 2018 Earnings and Host Conference Call and Webcast PR Newswire
Sep-28-18 10:07AM  Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs Zacks
07:30AM  Allergan And The Allergan Foundation Support Breast Cancer Patients With New Charitable Programs PR Newswire
Sep-27-18 03:10PM  Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA Zacks
Sep-26-18 07:30AM  Allergan Announces FDA Acceptance of Supplemental New Drug Application For VRAYLAR® (cariprazine) PR Newswire
Sep-21-18 01:56PM  4 Stocks John Paulson and Paul Tudor Jones Agree On GuruFocus.com
11:22AM  Why an Exton pharma firm will benefit from Almirall's $550M deal with Allergan American City Business Journals
10:21AM  3 Drug/Biotech Stocks in Focus on World Alzheimer's Day Zacks
Sep-20-18 07:10PM  [$$] Gormley's Take: Future of Aesthetic Medicine Not Just Another Pretty Face The Wall Street Journal
07:30AM  Allergan Teams Up with Actor Scott Eastwood to Encourage Recognition of World Alzheimer's Day on September 21st PR Newswire
Sep-19-18 08:53AM  Allergan Announces Plans to Build First Medical Aesthetics Innovation Center in Chengdu China PR Newswire
01:05AM  Teva Wins Approval From FDA for Blockbuster Migraine Drug InvestorPlace
Sep-17-18 04:11PM  JMP: Changing Competitive Landscape Makes Revance Less Appealing Benzinga
10:38AM  Allergan Frown Lines Study Passes Test on Higher Botox Dose Zacks
Sep-14-18 04:15PM  Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines PR Newswire
03:25PM  FDA plans meeting to discuss safety data on breast implants Associated Press
03:00PM  Allergan Highlights Key Growth Drivers for Medical Aesthetics PR Newswire
01:49PM  Allergan says revenue from aesthetics unit may double by 2025 Reuters
12:55PM  [$$] The Curious New Botox Ads The Wall Street Journal
12:08PM  Who Really Owns Allergan plc (NYSE:AGN)? Simply Wall St.
11:34AM  Allergan says revenue from aesthetics unit may double by 2025 Reuters
10:31AM  [$$] Allergan Acquires Neurotoxins Startup Bonti The Wall Street Journal
09:30AM  Is Allergan (AGN) a Great Stock for Value Investors? Zacks
09:15AM  Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline PR Newswire
Sep-12-18 12:00PM  Why Bausch Health Companies Inc. Stock Is Booming Today Motley Fool
07:30AM  Allergan Unveils Spotlyte, A First-In-Category Digital Hub Designed To Educate Consumers About Medical Aesthetic Treatments PR Newswire
Sep-10-18 08:00AM  Allergan to Host Medical Aesthetics Day Event on September 14, 2018 PR Newswire
Sep-09-18 08:44PM  Cheap Custom-Made Versions of High-Cost Drugs Spur Backlash The Wall Street Journal
06:13PM  Insider Buys Of The Week: Allergan, American Homes 4 Rent, Tiffany Benzinga
01:55PM  Top Insider Buys Highlight for the Week of Sept. 7 GuruFocus.com
10:18AM  Cheap Custom-Made Versions of High-Cost Drugs Spur Backlash The Wall Street Journal
Sep-06-18 09:00AM  The Most Exciting Advance in Skincare is Here: Introducing the SkinMedica® LUMIVIVE System PR Newswire
Sep-05-18 02:24PM  Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition TheStreet.com
Aug-31-18 01:28PM  One sector is beating tech this quarter, but one technician sees a ceiling CNBC
Aug-30-18 08:00AM  Allergan to Present at the 2018 Wells Fargo Healthcare Conference PR Newswire
Aug-29-18 05:12PM  Time to Take Some Profits in Sarepta Therapeutics Stock InvestorPlace
12:00AM  Ketamine is becoming a popular treatment for depression, but it acts like an opioid, study suggests CNBC
Aug-24-18 08:54AM  Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs Zacks
08:16AM  3 Relatively Safe Ways to Invest in Gene Editing Motley Fool
Aug-23-18 08:00PM  Alibaba's Domestic Focus; Allergan Takes Another Lump -- ICYMI TheStreet.com
11:24AM  AbbVie Posts Positive Data on Elagolix for Uterine Fibroids Zacks
10:37AM  Why Tevas Outlook Is Mixed InvestorPlace
Aug-22-18 03:19PM  5 Drug Stocks to Buy While the Pharma Sector Is on Sale InvestorPlace
02:49PM  Stocks Open Lower, Turn Mixed As Oil Prices, Retail Stocks Rally Investor's Business Daily
09:54AM  Ironwood's Linzess Gets Approval in Japan for New Indication Zacks
09:45AM  Allergan Falls on FDA's Rejection of Uterine Fibroids Drug Zacks
08:20AM  The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin Benzinga
Aug-21-18 05:53PM  FDA rejects Allergan's Esmya fibroid treatment Reuters
05:16PM  FDA declines to approve Allergan's Esmya Reuters
05:00PM  Allergan Receives Complete Response Letter from the U.S. Food and Drug Administration for Ulipristal Acetate New Drug Application PR Newswire
02:08PM  Allergan Has Finally Made a Base Pattern Traders Can Approach From the Long Side TheStreet.com
10:52AM  Hedge funds are moving away from tech and moving toward a new industry Yahoo Finance Video
07:20AM  Yahoo Finance Live: Market Movers - Aug 21st, 2018 Yahoo Finance Video
Aug-20-18 01:22PM  Final Trades: Adobe, Allergan, KWEB & Delta CNBC Videos
Aug-17-18 07:31AM  If I Had to Buy 1 Stock in August, It Would Be This One Motley Fool
Aug-16-18 08:48AM  10 Roughed-Up Stocks to Buy for a Recovery Rally Kiplinger
Aug-15-18 10:36AM  3 Stocks for Warren Buffett Fans Motley Fool
Aug-14-18 11:05AM  Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs Zacks
11:02AM  Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why Zacks
Aug-13-18 07:38AM  The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers Zacks
Aug-10-18 08:52AM  Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus Zacks
Aug-09-18 04:17PM  Editas Prepares for the Commercialization of EDIT-101 Motley Fool
Aug-08-18 01:14PM  Editas Medicine (EDIT) Q2 2018 Earnings Conference Call Transcript Motley Fool
08:03AM  Allergan Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process PR Newswire
Aug-07-18 10:24AM  Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down Zacks
Aug-06-18 04:01PM  Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101 PR Newswire
Aug-03-18 11:22AM  Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down Zacks
04:19AM  Spain's Almirall bets on dermatology with $650 mln U.S. deal Reuters
02:56AM  Spain's Almirall to buy U.S. dermatology portfolio from Allergan Reuters
Aug-02-18 07:42PM  Allergan sues Pfizer over costs of opioid litigation Reuters
04:48PM  Allergan sues Pfizer over costs of opioid litigation Reuters
04:16PM  Allergan sues Pfizer over costs of opioid litigation Reuters
02:31PM  Allergan Sues Pfizer Over Damages in Opioid Litigation Bloomberg
01:13PM  Allergan Sues Pfizer, King Over Opioid Litigation Costs Bloomberg
Jul-31-18 08:20AM  Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Allergan ACCESSWIRE
06:21AM  Earnings, Tariffs and Video Games in the Blitz CNBC
Jul-30-18 07:02PM  Cramer's lightning round: Buy into Allergan's roaring sto... CNBC Videos
06:50PM  Cramer's lightning round: Buy into Allergan's roaring stock below $180 CNBC
01:39PM  The Blitz: Earnings movers, plus a gaming stock under pre... CNBC Videos
08:00AM  Allergan Announces Third Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share PR Newswire
Jul-27-18 11:43AM  Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod Zacks
09:34AM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1 Zacks
09:14AM  Edited Transcript of AGN earnings conference call or presentation 26-Jul-18 12:30pm GMT Thomson Reuters StreetEvents
02:45AM  Pharma Favorites: 7 Healthy Picks in the Drug Sector Investopedia
Jul-26-18 08:00PM  Allergan Pushes Back on M&A Questions; Comcast Happy With Its Portfolio - ICYMI TheStreet.com
02:06PM  Allergan Announces $2 Billion Share Buyback Program, Raises Guidance TheStreet.com
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories. It also provides breast implants and tissue expanders; RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis; ocular implants; and Kybella, a non-surgical treatment for submental fullness. In addition, the company develops therapies for non-alcoholic steatohepatitis and other liver diseases; treatments for neurodegenerative disorders, including Alzheimer's disease; small molecule therapeutics that target inflammatory and fibrotic diseases; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and licensing agreements with Assembly Biosciences, Inc. MedImmune, and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COUGHLIN CHRISTOPHER JDirectorSep 06Buy190.6410,0001,906,39416,431Sep 07 08:31 AM
Boccuzi Joseph HDirectorAug 30Buy190.59900171,5313,885Sep 04 05:06 PM
FREYMAN THOMAS CDirectorAug 30Buy190.691,100209,7592,658Sep 04 05:07 PM
Basgoz NesliDirectorAug 30Sale190.051,055200,5037,359Sep 04 05:08 PM
Basgoz NesliDirectorAug 10Option Exercise81.161,889153,3119,248Aug 14 05:32 PM
Meury WilliamEVP & Chief Commercial OfficerMay 17Option Exercise68.1121,2521,447,47440,154May 21 05:21 PM
Meury WilliamEVP & Chief Commercial OfficerMay 17Sale154.5924,4253,775,86115,729May 21 05:21 PM
Hilado Maria TeresaExecutive Vice PresidentMar 15Buy167.39895149,81426,530Mar 19 09:36 AM
WALSH MATTHEW MEVP, Chief Financial OfficerMar 08Buy153.961,000153,96025,416Mar 08 10:44 AM
SAUNDERS BRENT LChairman, President and CEOMar 08Buy152.533,300503,349180,931Mar 08 10:25 AM
Boccuzi Joseph HDirectorMar 05Buy143.42900129,0781,862Mar 09 04:31 PM
WALSH MATTHEW MEVP, Chief Financial OfficerFeb 21Buy160.942,000321,88024,416Feb 22 04:25 PM
Meury WilliamChief Commercial OfficerFeb 14Option Exercise63.1723,6131,491,73778,600Feb 16 05:10 PM
Meury WilliamChief Commercial OfficerFeb 14Sale160.6258,8799,457,36919,721Feb 16 05:10 PM
BODINE CHRIS WDirectorDec 07Buy164.773,030499,25317,098Dec 07 05:21 PM
SAUNDERS BRENT LChairman, President and CEODec 06Buy164.744,600757,794186,377Dec 06 12:31 PM
COUGHLIN CHRISTOPHER JDirectorDec 05Buy163.3010,0001,633,00014,446Dec 05 04:16 PM
Meury WilliamChief Commercial OfficerDec 01Option Exercise78.8811,807931,33668,828Dec 04 06:21 PM
Meury WilliamChief Commercial OfficerDec 01Sale173.8911,8072,053,11957,021Dec 04 06:21 PM